Aurinia Pharmaceuticals Inc
| NASDAQ: AUPH | Healthcare / Biotechnology / Canada |
| 12.80 | -0.1600 | -1.23% | Vol 1.12M | 1Y Perf -15.68% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 12.72 | ASK | 12.79 | ||
| Open | 13.00 | Previous Close | 12.96 | ||
| Pre-Market | - | After-Market | 12.77 | ||
| - - | -0.03 -0.23% |
| Target Price | 29.75 | Analyst Rating | Strong Buy 1.16 | |
| Potential % | 132.42 | Finscreener Ranking | ★★★★★ 69.61 | |
| Insiders Trans % 3/6/12 mo. | 33/33/33 | Value Ranking | ★★★★+ 59.57 | |
| Insiders Value % 3/6/12 mo. | -74/-74/-74 | Growth Ranking | ★★★★★ 70.88 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -74/-74/-74 | Income Ranking | — - | |
| Market Cap | 1.63B | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 9.31 | Earnings Date | 13th May 2021 |
Today's Price Range 12.6913.00 | 52W Range 12.0120.50 | 5 Year PE Ratio Range -8.30-8.50 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.59% | ||
| 1 Month | -2.36% | ||
| 3 Months | -4.48% | ||
| 6 Months | -18.37% | ||
| 1 Year | -15.68% | ||
| 3 Years | 137.48% | ||
| 5 Years | 349.12% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -40.72 | |||
ROE last 12 Months | -28.02 | |||
ROA (5Y Avg) | -17.36 | |||
ROA last 12 Months | -25.14 | |||
ROC (5Y Avg) | -55.14 | |||
ROC last 12 Months | -59.59 | |||
Return on invested Capital Q | -5.50 | |||
Return on invested Capital Y | -29.85 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 70.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -14.50 | ||||
| 4.05 | ||||
| 32.89 | ||||
| - | ||||
| -31.50 | ||||
| -0.74 | ||||
| 4.11 | ||||
| 3.15 | ||||
| 1.09B | ||||
| Forward PE | -62.57 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.50 | ||||
| 13.10 | ||||
| 0.02 | ||||
| 0.02 | ||||
| -471.00 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| -194.50 | ||||
| -191.80 | ||||
| -14 421.50 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 50.92M | ||||
| 0.40 | ||||
| 299.88 | ||||
| 125.80 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.31 | -0.05 | 83.87 |
| Q03 2020 | -0.22 | -0.28 | -27.27 |
| Q02 2020 | -0.23 | -0.26 | -13.04 |
| Q01 2020 | -0.20 | -0.15 | 25.00 |
| Q04 2019 | -0.21 | -0.29 | -38.10 |
| Q03 2019 | -0.19 | -0.21 | -10.53 |
| Q02 2019 | -0.15 | -0.17 | -13.33 |
| Q01 2019 | -0.16 | -0.16 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.34 | -36.00 | Negative |
| 6/2021 QR | -0.30 | -130.77 | Negative |
| 12/2021 FY | -1.09 | -25.29 | Negative |
| 12/2022 FY | -0.21 | 25.00 | Positive |
| Next Report Date | 13th May 2021 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.12M |
| Shares Outstanding | 127.45M |
| Trades Count | 7.69K |
| Dollar Volume | 91.48M |
| Avg. Volume | 4.47M |
| Avg. Weekly Volume | 1.08M |
| Avg. Monthly Volume | 2.79M |
| Avg. Quarterly Volume | 4.62M |
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 12.8 per share at the end of the most recent trading day (a -1.23% change compared to the prior day closing price) with a volume of 1.16M shares and market capitalization of 1.63B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.
The one-year performance of Aurinia Pharmaceuticals Inc stock is -15.68%, while year-to-date (YTD) performance is -7.45%. AUPH stock has a five-year performance of 349.12%. Its 52-week range is between 12.01 and 20.5, which gives AUPH stock a 52-week price range ratio of 9.31%
Aurinia Pharmaceuticals Inc currently has a PE ratio of -14.50, a price-to-book (PB) ratio of 4.05, a price-to-sale (PS) ratio of 32.89, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.14%, a ROC of -59.59% and a ROE of -28.02%. The company’s profit margin is -%, its EBITDA margin is -191.80%, and its revenue ttm is $50.92 Million , which makes it $0.40 revenue per share.
Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 13th May 2021.
The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.16), with a target price of $29.75, which is +132.42% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 12.96, ATR14 : 0.94, CCI20 : -111.89, Chaikin Money Flow : -0.08, MACD : -0.61, Money Flow Index : 38.72, ROC : -14.08, RSI : 36.65, STOCH (14,3) : 26.37, STOCH RSI : 0.40, UO : 49.92, Williams %R : -73.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George M. Milne (Buy at a value of $65 000), Neil Solomons (Option Excercise at a value of $120 800), Neil Solomons (Sold 40 000 shares of value $539 600 ), Stephen P. Robertson (Buy at a value of $14 526)
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
CEO: Peter S. Greenleaf
Telephone: +1 250 708-4272
Address: 4464 Markham Street, Victoria V8Z 7X8, BC, CA
Number of employees: 294
